|
(MoneyNewsWire.Net, April 19, 2018 ) The Asia-Pacific market for nuclear medicine Radiopharmaceuticals is estimated at $855 million in 2015 and is expected to reach $1670 million by 2020, growing at a CAGR of 14.3%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
Browse market data tables and in-depth TOC of the Asia-pacific Nuclear Medicine Radiopharmaceuticals Market to 2020 @ https://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/
Increasing incidence of chronic diseases such as cancer and cardiac ailments, advancements in technology, increasing demand for SPECT and PET applications along with the growing public awareness for healthcare are fuelling the growth of the market. Further, new developments such as Integration of X ray tomography (CT) into SPECT provide an excellent diagnostic tool in medical imaging and are considered to be a driving factor for the growth of the market. Strict regulatory framework poses a potential hurdle to translational research and clinical investigations. Reimbursement issues are also blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are the key factors restraining the Asia-Pacific nuclear medicine Radioisotopes market.
The market of radiopharmaceuticals is segmented into Diagnostic radioisotopes and Therapeutic radioisotopes. Diagnostic radioisotope market is further sub segmented into SPECT (Technetium-99m, Thallium-201 Gallium-67, Iodine) and PET (Fluorine-18, Rubidium-82) radioisotopes. Therapeutic radioisotopes cover Beta emitters (Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177), Alpha Emitters (Radium-223) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192). By application radiopharmaceuticals market is segmented into (cardiology, lymphoma, thyroid, neurology oncology, and others). Furthermore, on the basis of geography, the Asia-Pacific Market is analysed under various regions namely, India, China, Japan and South Korea. India and China hold a potential market for radioisotope due to rising healthcare and increasing demand for different radioisotopes in various treatments and applications.
Free sample of the report is available @ https://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/request-sample
Diagnostic Radioisotopes is the dominating segment and account for around 90 % of the radiopharmaceuticals market while therapeutic radioisotopes contribute 10% of the market. Based on type of radioisotopes the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18, Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have been gaining the business interest of major research institutes and PET isotope players in the recent times. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
Some of the key players influencing the Asia-Pacific nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
Inquire before buying @ https://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/inquire
The scope of the report provides:
• The evaluation of the current market for your product or services and the future implications of the market
• Addresses the opportunities by better understanding the market through size estimates and growth rate analysis to forecast the market for the future
• Extensive segmentation to understand the dynamics of market at a very granular level by splitting down the market to the smallest segment
• Addresses the key market dynamics involving the drivers, restraints and challenges with an aim of providing insights for gaining market share
• The factors responsible for the shaping of the industry as it is as a result of competitive environment is analyzed through Porter’s Five Forces
• The effects of political, economic, social, technological, legal and environmental factors on the industry is analyzed through PESTLE analysis to better understand the aspects of strategic management required to comply with the exogenous and endogenous factors
• Strategic evaluation of the key players to gain insights of their performance allowing access to their product portfolio, financial performance and the strengths of their business strategic developments
• Comparative study of the firms across the industry measuring their performances based on market share and recent activities in order to achieve competitive intelligence
• Equip you with the information providing with the investment opportunities in the industry
Looking for more? If you are in need of a specific research study, we have an expertise in undertaking a customized study and will aid to meet your research requirement to the fullest.
Order your copy of the report: https://www.marketdataforecast.com/cart/buy-now/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail:abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
Follow us @ https://in.linkedin.com/company/market-data-forecast
Market Data Forecast.
Abhishek Shukla
+1-888-702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
|
